Microalbuminuria as a target to improve cardiovascular and renal outcomes

被引：84
作者：
Basi, Seema [1 ]
Lewis, Julia B. [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol, Nashville, TN 37232 USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2006年 / 47卷 / 06期
关键词：
microalbuminuria; kidney disease; cardiovascular disease; angiotensin-converting enzyme inhibitor; angiotensin II receptor antagonist;
D O I：
10.1053/j.ajkd.2006.02.182
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Albuminuria is a cardiovascular and renal risk factor in patients with diabetes, patients with hypertension, and the general population. Risk has been shown to increase continuously with increasing urinary albumin levels, starting at levels that once were considered normal. This association is maintained even after adjusting for numerous other factors. Studies also established that a decrease in albuminuria leads to improvement in both cardiovascular and renal outcomes. These data suggest that urinary albumin should be measured routinely and treated to afford cardiovascular and renoprotection.
引用
收藏
页码：927 / 946
页数：20
相关论文
共 107 条
  • [1] Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial
    Agodoa, LY
    Appel, L
    Bakris, GL
    Beck, G
    Bourgoignie, J
    Briggs, JP
    Charleston, J
    Cheek, D
    Cleveland, W
    Douglas, JG
    Douglas, M
    Dowie, D
    Faulkner, M
    Gabriel, A
    Gassman, J
    Greene, T
    Hall, Y
    Hebert, L
    Hiremath, L
    Jamerson, K
    Johnson, CJ
    Kopple, J
    Kusek, J
    Lash, J
    Lea, J
    Lewis, JB
    Lipkowitz, M
    Massry, S
    Middleton, J
    Miller, ER
    Norris, K
    O'Connor, D
    Ojo, A
    Phillips, RA
    Pogue, V
    Rahman, M
    Randall, OS
    Rostand, S
    Schulman, G
    Smith, W
    Thornley-Brown, D
    Tisher, CC
    Toto, RD
    Wright, JT
    Xu, SC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21): : 2719 - 2728
  • [2] Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects
    Ahmad, J
    Shafique, S
    Abidi, SMA
    Parwez, I
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2003, 60 (02) : 131 - 138
  • [3] Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: A case for albuminuria
    Anavekar, NS
    Gans, DJ
    Berl, T
    Rohde, RD
    Cooper, W
    Bhaumik, A
    Hunsicker, LG
    Rouleau, JL
    Lewis, JB
    Rosendorff, C
    Porush, JG
    Drury, PL
    Esmatjes, E
    Raz, I
    Vanhille, P
    Locatelli, F
    Goldhaber, S
    Lewis, EJ
    Pfeffer, MA
    [J]. KIDNEY INTERNATIONAL, 2004, 66 : S50 - S55
  • [4] [Anonymous], 2005, DIABETES CARE, V28, pS4
  • [5] Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals -: The Framingham heart study
    Ärnlöv, J
    Evans, JC
    Meigs, JB
    Wang, TJ
    Fox, CS
    Levy, D
    Benjamin, EJ
    D'Agostino, RB
    Vasan, RS
    [J]. CIRCULATION, 2005, 112 (07) : 969 - 975
  • [6] Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study
    Arnold, JMO
    Yusuf, S
    Young, J
    Mathew, J
    Johnstone, D
    Avezum, A
    Lonn, E
    Pogue, J
    Bosch, J
    [J]. CIRCULATION, 2003, 107 (09) : 1284 - 1290
  • [7] Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria
    Asselbergs, FW
    Diercks, GFH
    Hillege, HL
    van Boven, AJ
    Janssen, WMT
    Voors, AA
    de Zeeuw, D
    de Jong, PE
    van Veldhuisen, DJ
    van Gilst, WH
    [J]. CIRCULATION, 2004, 110 (18) : 2809 - 2816
  • [8] Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy
    Atkins, RC
    Briganti, EM
    Lewis, JB
    Hunsicker, LG
    Braden, G
    de Crespigny, PJC
    DeFerrari, G
    Drury, P
    Locatelli, F
    Wiegmann, TB
    Lewis, EJ
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (02) : 281 - 287
  • [9] Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists
    Azizi, M
    Ménard, J
    [J]. CIRCULATION, 2004, 109 (21) : 2492 - 2499
  • [10] Berrut G, 1997, CLIN NEPHROL, V48, P92
12345678910